阿泰生命科学
ATAI
0.00
0.00
0.00%
阿泰生命科学
US · ATAI
#2575 按市值排名
上市于 2021
0.00
0.00
0.00%
实时 - 追踪5344个代码 - 心跳于249秒前
· 2026-10-16 09:30
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量减少了1家。
- 机构持股总比例下降了0.8个百分点。
机构持股
- 机构持股比例
- 54.78% -0.81pp
- 机构数量
- 271 -1
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund25.26%
VC/PE Fund19.94%
Hedge Fund5.49%
Family Office/Trust2.36%
Individual/Insider2.29%
Public Company0.96%
Government Pension Fund0.22%
Endowment Fund0.19%
Private Company0.19%
Other43.11%
主要股东 截至 2026-07-15
Apeiron Investment Group Limited
14.55% · 53.97M 股
BlackRock
6.90% · 25.57M 股
Deep Track Capital, LP
3.89% · 14.42M 股
Vanguard Capital Management, LLC
3.59% · 13.32M 股
Galaxy Group Investments LLC
2.28% · 8.47M 股
State Street Global Advisors
2.23% · 8.29M 股
Cosmo Mellen
2.07% · 7.66M 股
Geode Capital Management, LLC
1.87% · 6.93M 股
Adage Capital Management, L.P.
1.52% · 5.64M 股
UBS Asset Management
1.33% · 4.91M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 13次买入 · 37次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Apeiron Investment Group Limited | -- | 14.55% |
| Cosmo Mellen | Independent Non-Executive Director | 2.07% |
| Srinivas Rao | Co-Founder & CSO | 0.06% |
| Ryan Barrett | General Counsel | 0.04% |
| Anne Johnson | Chief Accounting Officer & Interim CFO | 0.04% |
| Florian Brand | Co-founder & CEO | 0.04% |
| Sahil Kirpekar | Chief Business Officer | 0.03% |
| Glenn Short | Former Senior Vice President of Early Development | 0.01% |
| Kevin Craig | Senior Vice President of Clinical Development | 0.00% |
| Andrea Smiley | Independent Member of Supervisory Board | 0.00% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-10 | Sabrina Johnson | Independent Member of Supervisory Board | Derivative Sale to Issuer | -455,968 | -- |
| 2026-09-10 | Laurent Fischer | Independent Supervisory Director | Derivative Sale to Issuer | -430,968 | -- |
| 2026-09-10 | Robert Hershberg | Non-Executive Directors | Derivative Sale to Issuer | -741,089 | -- |
| 2026-09-10 | Michael Faerm | Chief Financial Officer | Derivative Sale to Issuer | -1,275,000 | -- |
| 2026-09-10 | Michael Faerm | Chief Financial Officer | Derivative Sale to Issuer | -285,000 | -- |
| 2026-09-10 | Amir Kalali | Independent Member of Supervisory Board | Sale to Issuer | -4,666 | -- |
| 2026-09-10 | Amir Kalali | Independent Member of Supervisory Board | Derivative Sale to Issuer | -455,968 | -- |
| 2026-09-10 | Srinivas Rao | Co-Founder & CSO | Sale to Issuer | -216,442 | -- |
| 2026-09-10 | Srinivas Rao | Co-Founder & CSO | Derivative Sale to Issuer | -9,521,381 | -- |
| 2026-09-10 | Srinivas Rao | Co-Founder & CSO | Derivative Sale to Issuer | -442,000 | -- |
| 2026-09-10 | Scott Braunstein | Independent Supervisory Director | Derivative Sale to Issuer | -573,881 | -- |
| 2026-09-10 | Apeiron Investment Group Limited | -- | Sale to Issuer | -55,756,748 | -- |
| 2026-09-10 | Apeiron Investment Group Limited | -- | Derivative Sale to Issuer | -2,310,528 | -- |
| 2026-09-10 | Andrea Smiley | Independent Member of Supervisory Board | Sale to Issuer | -4,666 | -- |
| 2026-09-10 | Andrea Smiley | Independent Member of Supervisory Board | Derivative Sale to Issuer | -455,968 | -- |
| 2026-09-10 | Ryan Barrett | General Counsel | Sale to Issuer | -155,066 | -- |
| 2026-09-10 | Ryan Barrett | General Counsel | Derivative Sale to Issuer | -3,493,267 | -- |
| 2026-09-10 | Ryan Barrett | General Counsel | Derivative Sale to Issuer | -150,000 | -- |
| 2026-09-10 | Glenn Short | Former Senior Vice President of Early Development | Sale to Issuer | -42,333 | -- |
| 2026-09-10 | Glenn Short | Former Senior Vice President of Early Development | Derivative Sale to Issuer | -2,935,367 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 09:30:00 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
阿泰生命科学 讨论区 0 条评论